Panagora Asset Management Inc Seagen Inc. Transaction History

Panagora Asset Management Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$187.64 - $206.25 $47,848 - $52,593	255 Added 2.84%	9,223 $1.78 Million
Q1 2023 May 11, 2023	BUY	$127.59 - $203.08 $12,503 - $19,901	98 Added 1.1%	8,968 $1.82 Million
Q4 2022 Feb 13, 2023	BUY	$117.37 - $139.17 $395,419 - $468,863	3,369 Added 61.24%	8,870 $1.14 Million
Q1 2022 May 12, 2022	SELL	$119.61 - $157.85 $1.8 Million - $2.37 Million	-15,011 Reduced 73.18%	5,501 $792,000
Q4 2021 Feb 10, 2022	SELL	$142.57 - $190.86 $9.14 Million - $12.2 Million	-64,105 Reduced 75.76%	20,512 $3.17 Million

Q3 2021 Nov 10, 2021	BUY	$142.45 - $169.82 $2.93 Million - $3.49 Million	20,567 Added 32.11%	84,617 $14.4 Million
Q2 2021 Aug 11, 2021	SELL	$135.08 - $161.1 $508,306 - $606,219	-3,763 Reduced 5.55%	64,050 $10.1 Million
Q1 2021 May 12, 2021	BUY	$137.51 - $190.8 $5.8 Million - $8.04 Million	42,148 Added 164.22%	67,813 $9.42 Million
Q4 2020 Feb 10, 2021	SELL	$164.63 - $211.93 $1.55 Million - $2 Million	-9,422 Reduced 26.85%	25,665 $4.5 Million
Q3 2020 Nov 13, 2020	BUY	$145.95 - $195.69 $5.12 Million - $6.87 Million	35,087 New	35,087 $6.87 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Panagora Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Panagora Asset Management Inc with notifications on news.